Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (4979)	5/26/1998 11:58:00 PM
From: SnowShredder	Read Replies (1) \| Respond to of 9719

V1 & the rest of the VD crew, Do you have an opinion on SNRS, Sunrise Technologies, they have an eye laser, in late trials, to treat hyperopia and presbiopia. Currently, they are a BB stock, but they are supposed to get full Nasdaq listing soon. Thanks for your opinion, Where'd He Go?

To: Vector1 who wrote (4979)	5/28/1998 4:19:00 AM
From: Rocketman	Read Replies (1) \| Respond to of 9719

Good call on the ugly market, at least early in the day. It was good to see the general recovery by days end, but the biotechs got hit hard. This of course contradicts what the "analysts" say is the cause of the downdraft, ie. Asian financial conditions. If the market is dropping because Asian demand for our products is down, then one could be led to think that a sector which doesn't rely much on sales to Asia would do well while the ones who sell a lot to Asia would do poorly. Uhhhh, then why did biotech go down??? So, is this market just going to stay volatile with big swings, or is it going to end up moving a lot in one direction or the other. Seems to be a lot of talk about a correction.....will this be a self-fulfilling prophecy??? Man these ENMD guys sure love to spew the hype: <<<<<<<<<<<< Wednesday May 27, 5:45 pm Eastern Time EntreMed to test endostatin in monkeys By Carol Huang NEW YORK, May 27 (Reuters) - EntreMed Inc. hopes to begin preliminary studies on the effects of its highly-anticipated anti-cancer drug endostatin in monkeys this summer, a company executive said Wednesday. ''Perhaps endostatin will be at a stage this summer where we can look preliminarily at how the drug behaves in monkeys,'' said Edward Gubish, senior vice president of research and development. Gubish, who was appearing with EntreMed chief executive John Holaday at a specialty pharmaceuticals conference hosted by SBC Warburg Dillon Read Inc, also said the company hopes to increase production of endostatin and angiostatin this summer to 500 litres from 60 litres (132.1 U.S. gallons from 15.85). News of the drugs' effectiveness in battling cancerous tumors in mice earlier this month made headlines and caused shares of EntreMed to jump as much as 500 percent in one day. Holaday said Wednesday that the company is still hoping to start clinical trials of the drugs in 12 to 18 months. ''If we do it successfully, it will be the fastest drug ever taken through the regulatory process,'' he said. He added that the company is exploring various methods of using the drugs. He said the drugs might be used to shrink a tumor before surgery to an operable size, or the drugs could be used in conjunction with chemotherapy. EntreMed is working with Bristol-Myers Squibb on developing angiostatin. And Holaday said his company is in negotiations to find a partner for endostatin. ''We're evaluating potential partnerships at this time,'' he said. Holaday also said the company will be spending more money as it begins clinical trials. EntreMed has 41 million in the bank and no debt, but it would like to strengthen its financial position, he said. He added that the company is open to a range of options, including increasing its outstanding shares from the current float of about 12 million. ''I think there are plenty of opportunities to further our financial position. We are looking at a number of opportunities and at reinforcing our investment banking relationships,'' he said. >>>>>>>>>>> biz.yahoo.com Well, gee that should be worth another couple of hundred mil in market cap! If this sucker goes up much tomorrow, we need to short it big time! Rman